Long-acting biologics present specific challenges for immunogenicity assessment, particularly when residual drug interferes with ADA detection. In this case study, Ardena outlines how a drug-tolerant ADA assay was established for a high-dose monoclonal antibody, enabling reliable detection in samples with high circulating drug levels.
Discover how targeted optimisation of a PandA-based approach delivered a robust, regulatory-ready solution for early clinical development.
